Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis

Código QR

Loss of progesterone receptor membrane component 1 promotes hepatic steatosis via the induced de novo lipogenesis

Abstract Non-alcoholic fatty liver disease (NAFLD) results from triglyceride accumulation within the liver and some of them advances to non-alcoholic steatohepatitis (NASH). It is important to note that in NAFLD development, hepatic de novo lipogenesis (DNL) derives from excess carbohydrates and fat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sang R. Lee, Sun Woo Kwon, Pelin Kaya, Young Ho Lee, Jong Geol Lee, Globinna Kim, Geun-Shik Lee, In-Jeoung Baek, Eui-Ju Hong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Progesterone Receptor Membrane Component 1 (PGRMC1) Non-alcoholic Steatohepatitis (NASH) Non-alcoholic Fatty Liver Disease (NAFLD) NAFLD Development Excess Energy Conditions Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0178d83a786046cfa39dfbfd36639d30
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
por: Chengyuan Liang, et al.
Publicado: (2021)

Circulatory <i>Endothelin 1-</i>Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study
por: Reda Albadawy, et al.
Publicado: (2021)

Editorial: New Insights Into Understanding and Managing NAFLD
por: Óscar Escribano, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
por: Sue Shea, et al.
Publicado: (2021)

Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates
por: Philippe Garteiser, et al.
Publicado: (2021)

The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease
por: Hao Xu, et al.
Publicado: (2021)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Daniela Maria Tanase, et al.
Publicado: (2021)

Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease
por: Szanto KB, et al.
Publicado: (2019)

NON-ALCOHOLIC STEATOHEPATITIS IN CHILDREN − A PRACTICAL APPROACH WITH CASE REPORT
por: Ana Šinkovec, et al.
Publicado: (2021)

Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice
por: Camille Houron, et al.
Publicado: (2021)

Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease
por: Jiyeon Si, et al.
Publicado: (2021)

Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population
por: Magda Shaheen, et al.
Publicado: (2021)

The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease
por: Siyu Yu, et al.
Publicado: (2021)

The negative and detrimental effects of high fructose on the liver, with special reference to metabolic disorders
por: Mai BH, et al.
Publicado: (2019)

Diagnostics and treatment of non-alcoholic fatty liver disease with concomitant asthenic syndrome
por: Aleksandr I. Pavlov, et al.
Publicado: (2021)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar R, et al.
Publicado: (2018)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Paola Dongiovanni, et al.
Publicado: (2021)

Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
por: Rocío Gallego-Durán, et al.
Publicado: (2021)

Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians
por: Mahamid M, et al.
Publicado: (2018)

Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis
por: Sun Y, et al.
Publicado: (2019)

E-Selectin-Dependent Inflammation and Lipolysis in Adipose Tissue Exacerbate Steatosis-to-NASH Progression via S100A8/9Summary
por: Robim M. Rodrigues, et al.
Publicado: (2022)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli S, et al.
Publicado: (2019)

The Circulating Micro-RNAs (−122, −34a and −99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases
por: Hendy OM, et al.
Publicado: (2019)

Assessment of hepatic fatty acids during non-alcoholic steatohepatitis progression using magnetic resonance spectroscopy
por: Aline Xavier, et al.
Publicado: (2021)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus JS, et al.
Publicado: (2021)

PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation
por: Barbara Becattini, et al.
Publicado: (2021)

Differential Therapeutic Effects of Crataegus aronia and Simvastatin on the Hepatocyte Ultrastructure in Hepatic Steatosis
por: Al Humayed,Suliman, et al.
Publicado: (2017)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Justine Gillard, et al.
Publicado: (2022)

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
por: Ahmed Z, et al.
Publicado: (2018)

Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH
por: Hegazy MA, et al.
Publicado: (2020)

Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot Study
por: Antonio Gidaro, et al.
Publicado: (2021)

Risk of Non-Alcoholic Fatty Liver Disease in Xanthelasma Palpebrarum
por: Chen HW, et al.
Publicado: (2021)

Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease
por: Kaitlin Day, et al.
Publicado: (2021)

New targets for NAFLDKey points
por: Lucia Parlati, et al.
Publicado: (2021)

Correlation between Non-Alcoholic Fatty Liver Disease (NAFLD) fibrosis score (NFS) with Left Ventricular Mass Index (LVMI) in patients with NAFLD
por: Tri Ferry Rachmatullah, et al.
Publicado: (2021)

Current and Potential Therapies Targeting Inflammation in NASH
por: Somaya Albhaisi, et al.
Publicado: (2021)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Sandip Mukherjee, et al.
Publicado: (2021)

Hepatoprotective Effects of Tribulus terrestris Hydro-Alcholic Extract on Non-Alcoholic Fatty Liver- Induced Rats
por: Almasi,Fatemeh, et al.
Publicado: (2017)

Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity
por: Xin Xin, et al.
Publicado: (2021)

Intake of Beer, Wine and Spirits and Risk of Heavy Drinking and Alcoholic Cirrhosis
por: GRØNBÆK,MORTEN, et al.
Publicado: (2004)